Shijiazhuang Lonzeal Pharmaceuticals Co. Ltd.

Main purpose: Dolutegravir sodium tablets (50 mg, calculated as dolutegravir) provided by Shijiazhuang Longze Pharmaceutical Co., Ltd. were used as the test preparation. According to the relevant provisions of the bioequivalence test, the absorption rate and degree of dolutegravir sodium tablets (trade name: Tivicay®, specification: 50 mg, reference preparation) produced by Glaxo Smithkline Pharmaceuticals SA were compared in healthy humans to investigate the bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation dolutegravir sodium tablets and the reference preparation dolutegravir sodium tablets (Tivicay®, Tivicay®) in healthy subjects.

Main purpose: Lamivudine-tenofovir tablets (specification: 300mg/300mg) developed by Shijiazhuang Longze Pharmaceutical Co., Ltd. were used as the test preparation. According to the relevant provisions of the bioequivalence test, the absorption rate and degree of Lamivudine-tenofovir tablets (trade name: Cimduo®, specification: 300mg/300mg, reference preparation) of Mylan Laboratories Ltd were compared with those of Lamivudine-tenofovir tablets (trade name: Cimduo®, specification: 300mg/300mg, reference preparation) in healthy subjects to investigate the bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation Lamivudine-tenofovir tablets and the reference preparation Lamivudine-tenofovir tablets (trade name: Cimduo®) in healthy subjects.

The main purpose of the study was to use the indobufen tablets (0.2g) provided by Shijiazhuang Longze Pharmaceutical Co., Ltd. as the test preparation. According to the relevant provisions of the bioequivalence test, the absorption rate and degree of indobufen tablets (trade name: Ibustrin ®, specification: 200mg, reference preparation) certified by Laboratórios Pfizer, Lda. were compared in healthy humans to investigate the bioequivalence of the two preparations. Secondary purpose of the study was to observe the safety of the test preparation indobufen tablets and the reference preparation indobufen tablets (Ibustrin ®) in healthy subjects.